6-32040535-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PP3_StrongPP5_Very_Strong
The NM_000500.9(CYP21A2):c.1069C>T(p.Arg357Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000301 in 1,460,002 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000086 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000030 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
CYP21A2
NM_000500.9 missense
NM_000500.9 missense
Scores
7
6
2
Clinical Significance
Conservation
PhyloP100: 0.984
Genes affected
CYP21A2 (HGNC:2600): (cytochrome P450 family 21 subfamily A member 2) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and hydroxylates steroids at the 21 position. Its activity is required for the synthesis of steroid hormones including cortisol and aldosterone. Mutations in this gene cause congenital adrenal hyperplasia. A related pseudogene is located near this gene; gene conversion events involving the functional gene and the pseudogene are thought to account for many cases of steroid 21-hydroxylase deficiency. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.974
PP5
Variant 6-32040535-C-T is Pathogenic according to our data. Variant chr6-32040535-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 12152.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-32040535-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP21A2 | NM_000500.9 | c.1069C>T | p.Arg357Trp | missense_variant | 8/10 | ENST00000644719.2 | NP_000491.4 | |
CYP21A2 | NM_001128590.4 | c.979C>T | p.Arg327Trp | missense_variant | 7/9 | NP_001122062.3 | ||
CYP21A2 | NM_001368143.2 | c.664C>T | p.Arg222Trp | missense_variant | 8/10 | NP_001355072.1 | ||
CYP21A2 | NM_001368144.2 | c.664C>T | p.Arg222Trp | missense_variant | 7/9 | NP_001355073.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000858 AC: 13AN: 151542Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
13
AN:
151542
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0000301 AC: 44AN: 1460002Hom.: 0 Cov.: 38 AF XY: 0.0000330 AC XY: 24AN XY: 726382
GnomAD4 exome
AF:
AC:
44
AN:
1460002
Hom.:
Cov.:
38
AF XY:
AC XY:
24
AN XY:
726382
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Data not reliable, filtered out with message: AS_VQSR AF: 0.0000857 AC: 13AN: 151662Hom.: 0 Cov.: 33 AF XY: 0.0000809 AC XY: 6AN XY: 74156
GnomAD4 genome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
13
AN:
151662
Hom.:
Cov.:
33
AF XY:
AC XY:
6
AN XY:
74156
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:16Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency Pathogenic:10Other:1
Pathogenic, criteria provided, single submitter | clinical testing | DASA | Jan 05, 2022 | The c.1069C>T;p.(Arg357Trp) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 12152; OMIM: 613815.0003; PMID: 20301350; 10720040; 26804566; 26206692; 25227725; 24904866; 24077358; 23359698; 23166432; 21329531; 10496074; 9215318; 9215318; 30968594; 29996815; 26804566; 20301350; 26206692) - PS4. Well-established in vitro or in vivo functional studies support a damaging effect on the gene or gene product (PMID: 2303461, 21134444, 1644925) - PS3_moderate. The p.(Arg357Trp) was detected in trans with a pathogenic variant (PMID: 30968594; 29996815; 26804566; 26206692) - PM3_strong. Pathogenic missense variant in this residue have been reported (Clinvar ID: 988494) - PM5. The variant co-segregated with disease in multiple affected family members (PMID: 29996815; 27041116) - PP1. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 1997 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.002%). The variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported. In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.68; 3Cnet: 0.98). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000012152). Different missense changes at the same codon (p.Arg357Gln, p.Arg357Pro) have been reported to be associated with CYP21A2 related disorder (ClinVar ID: VCV000988494 / PMID: 9099839, 9187661). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | Jun 22, 2023 | The observed missense c.1069C>Tp.Arg357Trp variant in CYP21A2 gene has been reported previously in homozygous or compound heterozygous state in individuals affected with Congenital adrenal hyperplasia CAH Tippabathani et al., 2023. Experimental studies have shown that this missense change affects CYP21A2 function Chiou et al., 1190; Gaffney et al., 2010. This variant is reported with the allele frequency of 0.001% in the gnomAD Exomes. The frequency data for this variant in the population databases gnomAD is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. About 203 total individuals have variant depth in the 0 - 5 range in gnomAD database. This variant has been reported to the ClinVar database as Pathogenic multiple submitters. The amino acid Arg at position 357 is changed to a Trp changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Arg357Trp in CYP21A2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. Multiple lines of computational evidence Polyphen - Possibly Damaging, SIFT - Damaging, and MutationTaster - Disease causing automatic predict a damaging effect on protein structure and function for this variant. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Dec 21, 2023 | PS3, PM1, PM3_Very Strong, PM5, PP3 - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Lifecell International Pvt. Ltd | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 20, 2019 | NM_000500.7(CYP21A2):c.1069C>T(R357W) is classified as pathogenic in the context of congenital adrenal hyperplasia and is associated with the classic form of the disease. Sources cited for classification include the following: PMID 21134444, 10496074 and 23359698. Classification of NM_000500.7(CYP21A2):c.1069C>T(R357W) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM3_VeryStrong+PM2_Supporting+PP4 - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Dec 10, 2024 | PS3, PM1, PM2, PM3, PM5, PP3, PP5 - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 15, 2022 | - - |
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 31, 2022 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 357 of the CYP21A2 protein (p.Arg357Trp). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This missense change has been observed in individual(s) with classic salt-wasting, simple virilizing, and non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (PMID: 2303461, 23359698, 25227725, 26804566). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as R356W. ClinVar contains an entry for this variant (Variation ID: 12152). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CYP21A2 protein function. Experimental studies have shown that this missense change affects CYP21A2 function (PMID: 2303461, 21134444). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Aug 18, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 29, 2023 | The CYP21A2 c.1069C>T (p.Arg357Trp) variant (also known as R357W or R356W) has been reported in the published literature as being associated with a salt-wasting CAH phenotype (PMIDs: 14513879 (2003), 23359698 (2013), 26206692 (2015), 26804566 (2016)). Functional studies show that this variant causes loss of enzymatic activity (PMIDs: 2303461 (1990), 14513879 (2003)). The frequency of this variant in the general population, 0.00015 (3/19676 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Sep 17, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jun 29, 2023 | Frequency data for this variant in the general population cannot be distinguished from that of the CYP21P pseudogene, and are therefore uninformative in assessment of variant pathogenicity. In some published literature, this variant is referred to as p.Arg356Trp. In multiple individuals, this variant has been seen in trans with other recessive pathogenic variants in CYP21A2, suggesting this variant is also pathogenic. Assessment of experimental evidence suggests this variant results in abnormal protein function. Several studies show this variant causes loss of enzymatic activity (PMID: 26206692, 21329531, 14513879). - |
CYP21A2-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 17, 2023 | The CYP21A2 c.1069C>T variant is predicted to result in the amino acid substitution p.Arg357Trp. In the literature, this variant is also referred to as R356W. This variant has been reported to be associated with salt-wasting (SW) congenital adrenal hyperplasia (CAH) (see for example at Finkielstain et al. 2011. PubMed ID: 20926536; New et al. 2013. PubMed ID: 23359698). This is a common deleterious variant, which likely originated from the pseudogene CYP21A1P via gene conversion. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Pathogenic
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Benign
N
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Uncertain
D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;.;D;.
REVEL
Pathogenic
Sift
Pathogenic
D;.;D;.
Sift4G
Uncertain
D;.;T;.
Polyphen
D;D;.;D
Vest4
MutPred
Loss of disorder (P = 0.0366);Loss of disorder (P = 0.0366);.;Loss of disorder (P = 0.0366);
MVP
MPC
ClinPred
D
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at